A Phase II, Single-arm Study of Orally Administered BEZ235 as Second-line Therapy in Patients With Advanced or Metastatic Endometrial Carcinoma.
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 25 Apr 2014
At a glance
- Drugs Dactolisib (Primary)
- Indications Endometrial cancer
- Focus Therapeutic Use
- Sponsors Novartis
- 06 Jun 2012 Additional location (Turkey) added as reported by ClinicalTrials.gov.
- 28 Mar 2012 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 22 Dec 2011 Planned end date changed from 1 Oct 2013 to 1 Dec 2017 as reported by ClinicalTrials.gov.